|
|
|
|
|
Merck KGaA
|
|
Established in the year 1668 by Friedrich Jacob Merck, Merck KGaA is the Germany based pharmaceutical company having it’s headquarter situated at Darmstadt in Germany. Merck KGaA is also popularly known as German Merck or Merck Darmstadt. It is one of the oldest and still operationally going strong chemical and pharmaceutical enterprises across the world today. The company was privately owned until 1995 when it went public duly incorporated. The Merck family still has the majority of the company’s shares under their control empowering them to manage the corporate company.
Immediately after the WW-I episode, Merck lost their possession on their foreign units which included the Merck & Co – the company’s subsidiary located in the United States as well as Merck & Co known as Merck Sharp and Dome – MSD outside the United States and Canada which is currently an independent entity. Merck KGaA is supposed to operate chiefly in the member countries of the European Union.
The history of Merck is believed to be very interesting like the company’s roots dates back to the 17th century. During the year 1668, an archaic dispensing chemist named Friedrich Jacob Merck took-over the possession of the Engel-Apotheke or say Engel Pharmacy in Darmstadt in Germany.
Many recognized and successful products have been invented by Merck but currently the main concentration of the pharmaceutical R&D is on Oncology and Cardio-metabolic Care. In the earlier therapeutic segments, the company’s first sold product is Erbitux having Cetuximab for which the company has world-wide marketing rights except North America where it is sold by Bristol-Myers Squibb.
The other major products of the company include: Metformin, Bisoprolol and Digitoxin.
|
|
|
|
|
|
|
Bristal_Myers Squibb
, Eltana
, Senkyo Co
, Teisho Pharmaceutical
, Whyeth
, Forast Laboratories
, Chugei Pharmaceutical Co
, Metsubishi Pharma
, Sanophi Aventis
, Merk and Co
|
|
|
|
|
| Latest News About merck kgaa |
|
|
|
AP. FRANKFURT, Germany: German drugmaker Merck KGaA said Thursday that its quarter quarter profit 18 climbed percent after the firm, has revenue its Erbitux gefördert...More |
|
|
|
Merck KGaA plans to issue Euro general reference point connection... - Color
Color - 1, 2007 Damages FRANKFURT (AFX) - Merck (nyse: MRK - messages - of people) KGaA sees SOWED synergies of its union with Serono (nyse: SRA - messages - of people) of 200 mln Eurs through 2009,....More |
|
|
|
Merck climbs KGaA Q1 opg 11.4 pct to 321.3 mln Eurs - Color
Color - On the 18th Jan, 2007 FRANKFURT (AFX) - Merck KGaA said that its fourth quarter operating profit to 303.3 mln Eurs of 191.7 mln Eurs climbed, on 58.2 pct of the same period a year....More |
|
|
|
Merck KGaA confirms 77 Eurs per share all-cash.. - Color
Color - Damages 23, 2006>> DARMSTADT, Germany (AFX) - Merck KGaA plans to sell Schering AGand diagnosis businesses if the acceptance of the firm, industries source succeeds....More |
|
|
|
|
Merck KGaA’s ethical business has, to date, was been based on its diabetes and... Merck KGaA’s the largest advantage its RandD piping that contained is,....More |
|
|
|
German stockholders protection groups seek poet... - Color
Color - Dec 16, 2004 DARMSTADT, Germany (AFX) - Merck KGaA said that it will attain Schott AGand Lumitec OLED research and development project for igniting devices prototype,....More |
|
|
|
Merck KGaA announces new leadership - chemistry. de
International Heroldtribüne - On the 12th Jan, 2007 LONDON: Group pacific Texas, Cinven and Permira advisers may offer are for the generic drug division by Merck KGaA, in accordance with four people that trusted with that....More |
|
|
|
|
On 23 March 2000 Merck KGaA announced that its USA Lizenznehmer for Glucophage... the agreement, will furnish Merck KGaA $480000 to underpin research in,....More |
|
|
|
|
FRANKFURT (AFX) - its control cut Merck KgaA for revenue in the present year when it revealed a 22.6 pct slump in third quarter EBIT to 214.7 mln Eurs of 277.4....More |
|
|
|
|
DARMSTADT, Germany (AFX) - Merck KGaA said that it decided to interrupt development its Parkinsonand drug Sarizotan after analysis of phase III data,....More |
|
|
|
|
|
|
|